Unlocking the Power of Small Caps: Unveiling Key Forces (ELAB, DLA, INBS, BCAN, ZVSA)

In the ever-evolving world of stock investments, discovering the diamonds in the rough among small-cap companies can yield remarkable rewards. These underdogs are powered by a distinctive mix of essential factors and triggers that can thrust them into the spotlight. Today, we are highlighting five small-cap stocks, exploring the factors that unleash their potential and ignite investor interest.

Elevai Labs, Inc. (NASDAQ: ELAB) - Elevai Labs, Inc. shares closed last week's trading session at $0.65, experiencing a slight decrease of just over 2%. The company recently announced a significant milestone: the signing of an international distribution agreement with ILIA International Ltd. ("ILIA") for the Taiwanese market. The CEO expressed excitement over this partnership, citing ILIA's esteemed reputation in Taiwan's aesthetic industry. Recognizing the region's historical connection to exosome-based beauty products, the CEO anticipates rapid growth with the support of ILIA's extensive network. With increasing trading volume observed last week, attention is now focused on the resistance level at $0.70 as we await further updates from the company.

--

Delta Apparel Company (NYSE: DLA) - Delta Apparel Company's shares concluded last week's trading session with a notable increase of over 4%, reaching $2.52. In late February, the company revealed its agreement for the sale and long-term leaseback of its extensive campus in Fayetteville, North Carolina, spanning approximately 35 acres and comprising around 550,000 square feet of industrial space. This space serves various functions across the company's business units, including manufacturing, decoration, and distribution. The property is set to be sold for $23.5 million, with expected net proceeds of approximately $22 million after tax and transaction costs. The transaction is slated to close around May 1, 2024, subject to customary closing conditions. Delta Apparel intends to continue its operations at the Fayetteville campus seamlessly and will establish a long-term lease agreement with the purchaser, spanning an initial term of 10.5 years. As we await further updates on this transaction, our attention is drawn to the resistance breakthrough at $2.65.

--

Intelligent Bio Solutions Inc. (NASDAQ: INBS) - Intelligent Bio Solutions Inc. saw its company shares surge nearly 9% to $2.69 by the close of last week's trading session. At the end of February, the company unveiled a strategic partnership with Cliantha Research, a comprehensive Clinical Research Organization (CRO), to conduct a pivotal pharmacokinetic (PK) study as part of its FDA 510(k) clinical study roadmap. This pivotal step signifies a significant milestone for the company as it progresses along the 510(k) pathway. Harry Simeonidis, President and CEO of Intelligent Bio Solutions, expressed enthusiasm, stating, "Our collaboration with Cliantha and the initiation of our clinical studies plan mark pivotal moments in our 510(k) journey. We've meticulously outlined our plan and are dedicated to its execution. While challenges lie ahead, taking this crucial first step is paramount. Our focus remains on maintaining our trajectory for market entry in the US and broadening access to our groundbreaking screening solution." The company aims to validate through the PK study that fingerprint sweat measurement serves as a reliable substitute for traditional measurements obtained from blood, oral fluid, or urine samples in detecting opiate presence. Subject recruitment and screening for the PK study are slated for March and April 2024, with studies scheduled to commence in May 2024. Sample analysis is anticipated to conclude by the end of June 2024. As we anticipate further updates from the company, our attention is drawn to the resistance level at $2.80.

--

BYND Cannasoft Enterprises (NASDAQ: BCAN) - BYND Cannasoft Enterprises witnessed its company shares dip by 2% to $0.92 at the conclusion of last week's trading session. According to their recently filed annual report this month, the company expects to unveil the first fully functional prototype of the EZ-G Device in the early stages of the second quarter of 2024, with potential delays attributed to ongoing conflicts. This prototype is estimated to require an additional investment of approximately $350,000. The company intends to enter the market and commence global sales of the device in the second quarter of 2024, leveraging patents filed across various countries. To facilitate this market entry, the company must conduct testing on the prototype and initiate manufacturing of the EZ-G Device. Since the initial product iteration is therapeutic in nature, regulatory approvals are not deemed necessary. The company's regulatory consultant has confirmed that as long as the CBD products used in the device contain less than 0.03% tetrahydrocannabinol (THC), U.S. Food and Drug Administration (FDA) approval is not required. As we await further updates from the company, attention is directed toward the resistance threshold of $1.03.

--

ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) - ZyVersa Therapeutics, Inc.'s shares concluded the previous week's trading session with a 17% decline, closing at $4.99 following a reverse split on Friday. In late March, the company provided a business update, highlighting significant progress in advancing the development of their primary candidates. Stephen C. Glover, ZyVersa's Co-founder, Chairman, CEO, and President, remarked, "Throughout 2023 and early 2024, ZyVersa achieved considerable progress in advancing development of our two lead candidates." Key achievements included the initiation of a Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease, ongoing preclinical studies for indication expansion into Parkinson's disease, atherosclerosis, and obesity with Inflammasome ASC Inhibitor IC 100, and an expected IND submission for IC 100 by the end of the year. Glover expressed optimism for 2024, anticipating transformative milestones and positioning ZyVersa as a leading innovator in drug development for renal and inflammasome-mediated inflammatory diseases. Additionally, a scientific collaboration with experts at the University of Miami Miller School of Medicine to evaluate IC 100's potential in treating obesity and metabolic syndrome is slated to commence in Q2-2024, while Phase 2a clinical trials for VAR 200 in diabetic kidney disease patients are on track for H1-2024. A collaboration to assess IC 100's potential in treating atherosclerosis is expected to conclude in the first half of 2024. As we await further updates from the company, our attention will be focused on two key factors: firstly, a potential resistance break at the $5.15 level, and secondly, the consolidation around the $4.80 mark. It's worth noting that the float is currently around 530k.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.